Arax Advisory Partners’s Inhibikase Therapeutics IKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$112K Buy
54,421
+47,300
+664% +$108K ﹤0.01% 2739
2026
Q2
$14.5K Buy
7,121
+7,072
+14,433% +$12.7K ﹤0.01% 4165
2026
Q1
$82 Buy
+49
New +$87 ﹤0.01% 3629
2025
Q4
– Sell
-86
Closed -$139 – 4294
2025
Q3
$139 Buy
+86
New +$149 ﹤0.01% 3477

Other funds holding IKT

Arax Advisory Partners's IKT Position: Q3 2026 in Review

Arax Advisory Partners increased its Inhibikase Therapeutics (IKT) stake by 664% in Q3 2026, buying an estimated $108K and bringing the position to 54,421 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #2739.

Arax Advisory Partners first reported a position in IKT in Q3 2025 and has held it in 4 quarters since. 110 funds tracked by Wall St. Rank hold IKT as of Q3 2026.

  • Arax Advisory Partners held 54,421 shares of Inhibikase Therapeutics worth $112K as of Q3 2026.
  • Arax Advisory Partners bought 47,300 Inhibikase Therapeutics shares in Q3 2026, an estimated $108K.
  • Inhibikase Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #2739 holding.
  • Arax Advisory Partners first reported a position in Inhibikase Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 110 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.